Comorbidities Articles

Discover more about the comorbidities of NASH / NAFLD through articles on NASH commentary content ▶ from a study obtained from expert doctors worldwide.

Phospholipid depletion and NAFLD pathophysiology: findings from lipidomics

Authors: Mocciaro G, Allison M, Jenkins B et al.
Published in Molecular Metabolism (April 2023)
Along with its association with metabolic syndrome, NAFLD is closely linked with mixed dyslipidaemia (reduced high-density lipoprotein cholesterol (HDL-C) and increased very low-density lipoprotein triglycerides (VLDL-TG)).
Read More

Cardiovascular disease in MAFLD versus NAFLD: a review

Authors: Kang MK, Lee YR, Jang SY et al
Published in Hepatol Int (April 2023)
Changing the terminology from NAFLD, non-alcoholic fatty liver disease, to MAFLD, metabolic dysfunction-associated fatty liver disease, has been an ongoing debate. MAFLD is based upon an individual having hepatic steatosis, as well as either type 2 diabetes mellitus, obesity (or being overweight) or if at a normal weight, two or more metabolic risk abnormalities.
Read More

The “Perfect” NASH Biomarker: an Unrealistic Pursuit?

Authors: Sebastiani G
Published in Lancet Gastroenterol Hepatol 2023
Seeking the perfect NASH biomarker may be unrealistic; versatility is key. A diverse biomarker pool adapts to varied clinical contexts and settings. FIB-4, a cost-effective marker, can be supplemented by complex multimarkers for NASH therapeutic trials. Embracing diagnostic imperfections is crucial for flexible biomarker algorithms.
Read More

Cardiovascular Risk in Patients with NAFLD and Inflammatory Bowel Diseases

Authors: Kablawi D, Aljohani F, Palumbo CS et al.
Published in Crohns Colitis 360 2023
NAFLD's prevalence in IBD patients raises concerns for cardiovascular risk. The study found doubled atherosclerotic cardiovascular disease risk in IBD patients with NAFLD. Transient elastography may predict cardiovascular risk in IBD patients. Targeted risk assessments are crucial for IBD patients with NAFLD.
Read More

T2D-Related Complications and its Impact on Fibrosis Levels: an Emerging Association?

Authors: Trivedi HD, Tran Q, Fricker Z et al.
Published in Annals of hepatology 2023
Patients with T2D complications have a 4.5x greater risk of developing fibrosis, independent of HbA1c levels. FIB-4 index can help identify diabetic patients at highest risk, improving primary care screening.
Read More

NAFLD and incident chronic kidney disease

Authors: Kaps L, Labenz C, Galle PR, et al.
Published in United European Gastroenterol J 2020
The association of NAFLD and CKD has been established before. The aim of this large-scale database study was to investigate the role of NAFLD on emerging CKD, the emergence of end-stage renal disease and the identification of additional risk factors which may increase the risk for CKD in Germany...
Read More

Diabetic kidney disease, cardiovascular disease and NAFLD

Authors: Perdomo CM, Garcia-Fernandez N, Escalada J.
Published in J Clin Med 2021
NAFLD, cardiovascular disease and chronic kidney disease share a common pathophysiology including insulin resistance, oxidative stress, chronic inflammation, dysbiosis and genetic susceptibilities. The aim of this review by C. M. Perdomo et al...
Read More

NAFLD and acute stroke: factors associated at admission

Authors: Mori T, Yoshioka K, Tanno Y.
Published in Hepatol Int 2021
This retrospective study by T. Mori et al. (Shanghai Jiao Tong University School of Medicine, China) aimed to investigate NAFLD frequency and identify factors associated with NAFLD presence at acute stroke admission.

The authors included stroke patients admitted from 2016 to 2019, within 24 h of onset...

Read More